EXTON, Pa., January 14, 2019 – AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech materials, has entered into an agreement with Boehringer Ingelheim to acquire its subsidiary Malgrat Pharma Chemicals, S.L.U. (MPC). Located in Spain, MPC manufactures synthetic pharmaceutical active ingredients used for pharmaceutical products that are produced by chemical synthesis.
By acquiring MPC, AGC will have its first FDA-registered site in Europe in the synthetic pharmaceutical contract development and manufacturing organization (CDMO) business. The acquisition remains subject to approval from the relevant antitrust authorities and the fulfillment of closing conditions under the share purchase agreement.
MPC has vast experience manufacturing commercialized synthetic pharmaceuticals that are compliant with current Good Manufacturing Practice (cGMP) standards, as well as compounds in clinical development on a range of scales.
Leveraging AGC’s fluorination technologies, extensive in-house drug discovery experience, and CDMO business in Japan, the acquisition will enable AGC to cater its CDMO services to European customer requirements and expand its presence in that market.
The AGC Group’s “AGC plus” management policy identifies life sciences as one of its strategic businesses. AGC will continue to actively invest in this field to provide globally unified high-quality services to customers in both the synthetic drug and biopharmaceutical businesses. By maximizing the synergies of each location, the group’s technical capabilities will be enhanced, making it possible to better contribute to pharmaceutical companies, patients and wider society in general.
About the AGC Group
AGC Inc. (Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs 50,000 people worldwide and generates annual sales of approximately 1.5 trillion Japanese yen through business in about 30 countries. For more information, please visit www.agc.com/en.
About Boehringer Ingelheim
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.
English
Customer & product inquiries: 1-800-424-7833
